VANCOUVER, BC / ACCESS Newswire / December 16, 2025 / Tactical Resources Corp. (TSXV:RARE)(OTC PINK:USRED) ("Tactical" or the "Company"), a mineral exploration and development company, is pleased to announce that, at the annual general and special meeting (the "Meeting") of holders of common shares ("Shareholders") held today, Shareholders overwhelmingly voted in favour of the special resolution (the "Arrangement Resolution") to approve the previously announced plan of arrangement (the "Arrangement") entere ...

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best biotech stocks to buy according to Wall Street analysts. On December 4, Citi analyst Yigal Nochomovitz reiterated a Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and set a $103 price target. The positive stance aligns with a Consensus Strong Buy rating from 13 Wall Street analysts, comprising 12 Buys and 1 Hold. Is Ultragenyx Pharmaceutical Inc. (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts? The ...

Core Viewpoint - Century Lithium Corp. has announced significant findings regarding the recovery of rare earth elements (REEs) from its Angel Island Lithium Project, indicating the potential for REEs to become a strategically important by-product alongside lithium carbonate production [1][9]. Summary by Sections REE Recovery Process - The company utilized a patent-pending chloride-based process combined with targeted ion-exchange, achieving high recoveries of REEs from a bulk sample of claystone [1][2]. - The claystone sample contained 0.024% total rare earth oxides (TREO) and 1101 ppm lithium, with REE distribution showing approximately 75% light rare earth elements and 25% heavy rare earth elements [2][3]. Testing Results - Chloride leaching yielded solution concentrations of 210 mg/l lithium and 36 mg/l TREO, demonstrating that REEs can be extracted under the same conditions as lithium [3]. - Ion-exchange tests showed high recovery rates for various REEs, with total REO recovery reaching 99.6% [4][5]. Strategic Importance - The Angel Island project is expected to process between 2.75 to 5.5 million tonnes of claystone annually, generating 10 to 20 million tonnes of leach solution per year, which could translate into significant quantities of REEs [8]. - The project is positioned to contribute meaningfully to North America's critical mineral supply chain, enhancing the company's revenue streams [2][9]. Future Development - Century Lithium is currently focused on further reserve definition and metallurgical testing before evaluating the economic contribution of REE recovery [9]. - The company is committed to completing an updated feasibility study and advancing permitting for the Angel Island project, which is crucial for its development [9][12].

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Summary of Ultragenyx Pharmaceutical FY Conference Call Company Overview - **Company**: Ultragenyx Pharmaceutical (NasdaqGS:RARE) - **Focus**: Development and commercialization of drugs for patients with rare diseases, particularly Osteogenesis Imperfecta (OI) and Angelman syndrome [2][26] Key Points Product Pipeline and Development - **Current Products**: Success with Crysvita, supported by Mepsevii, Evkeeza, and Dojolvi [2] - **Upcoming Data**: Anticipation for phase three data readouts, particularly for Osteogenesis Imperfecta [2] - **Setrusumab**: Expected to show significant results in both Orbit and Cosmic studies, with a focus on the probability of success [5][6] Financial Strategy - **Royalty Financing**: Initiated due to the delay in potential revenue from the Sanfilippo program, allowing for a stronger balance sheet without diluting stock [3] Clinical Trials - **Orbit and Cosmic Studies**: Both studies are designed to be reported together, with confidence in their success [4] - **Effect Size Expectations**: A treatment effect size of 30% to 40% is considered clinically meaningful, with a powered expectation of at least 50% [6][7] - **Rescue Treatment Protocol**: Ethical considerations in allowing patients to receive rescue treatment if they experience high fracture rates [9][10] Commercial Considerations - **Pricing Strategy**: Pricing for Osteogenesis Imperfecta will be informed by the successful launch of Crysvita [11] - **Duration of Treatment**: Setrusumab is expected to be a lifelong treatment due to its mechanism of action [12] Patient Demographics - **Trial Composition**: Orbit phase three includes approximately 50% type 3 and 4 patients, with a commercial mix of about 60% type 1 and 38% type 3 and 4 patients [14][15] Confidence in Data - **Confidence Level**: High confidence in the upcoming data readout for Setrusumab, supported by consistent results in earlier phases [16] Angelman Syndrome Program - **Phase 1/2 Study**: Enrollment of 74 patients, with ongoing discussions about data release prior to the next phase [17] - **Safety Monitoring**: Close monitoring of lower extremity weakness, with mild cases reported and resolved quickly [18][19] - **Dropout Rates**: Expected to remain low due to the nature of the study and the potential benefits for patients [19] Developmental Outcomes - **Cognitive Improvement**: Unique potential to improve cognition and communication in patients with Angelman syndrome, rather than just preventing deterioration [22] - **Primary Endpoint Focus**: Cognition is the primary endpoint, followed by communication and motor skills [25] Future Outlook - **Gene Therapy Programs**: Continued focus on gene therapy programs, with upcoming PDUFA dates for Sanfilippo and GSD1A expected to lead to successful launches [26]

PresentationYigal NochomovitzCitigroup Inc., Research Division We can get started. Welcome, everyone. I'm Yigal Nochomovitz, one of the biotech analysts at Citi, and welcome to our Global Healthcare Conference in Miami. So our next session is with Ultragenyx. We have the Chief Medical Officer, Eric Crombez. Eric, welcome. Thank you for making the trip. We've been covering you for many years and have been a lot of progress. ...

Core Viewpoint - Volvo Cars, based in Sweden, has reported a significant decline in sales for November, continuing a downward trend observed throughout the year due to trade tariffs and weakened demand in the United States [1] Company Summary - November sales for Volvo Cars have slumped, indicating ongoing challenges faced by the company [1] - The decline in sales is attributed to external pressures such as trade tariffs and a decrease in consumer demand, particularly in the U.S. market [1] Industry Summary - The automotive industry is experiencing pressures from trade tariffs, which are impacting sales figures for companies like Volvo Cars [1] - There is a notable subdued demand in the U.S. market, contributing to the overall decline in sales for the industry [1]

Ultragenyx Pharmaceutical (NasdaqGS:RARE) FY 2025 Conference December 02, 2025 03:15 PM ET Company ParticipantsEric Crombez - Chief Medical OfficerConference Call ParticipantsYigal Nochomovitz - Biotech AnalystYigal NochomovitzWe can get started. Welcome, everyone. I'm Yigal Nochomovitz, one of the biotech analysts at Citi, and welcome to our Global Healthcare Conference in Miami. So our next session is with Ultragenyx. We have the Chief Medical Officer, Eric Crombez. Eric, welcome. Thank you for making the ...

Ultragenyx Pharmaceutical (NasdaqGS:RARE) FY 2025 Conference December 02, 2025 03:15 PM ET Company ParticipantsEric Crombez - Chief Medical OfficerConference Call ParticipantsYigal Nochomovitz - Biotech AnalystYigal NochomovitzWe can get started. Welcome, everyone. I'm Yigal Nochomovitz, one of the biotech analysts at Citi, and welcome to our Global Healthcare Conference in Miami. So our next session is with Ultragenyx. We have the Chief Medical Officer, Eric Crombez. Eric, welcome. Thank you for making the ...

Financial Data and Key Metrics Changes - The company is focused on the upcoming data readout for setrusumab, which is expected by the end of December or January, marking a significant near-term value driver [2][34] - The company has achieved a 67% reduction in fracture rates from baseline in the phase 1/2 study, indicating strong efficacy [7][15] Business Line Data and Key Metrics Changes - The company is advancing its Osteogenesis Imperfecta (OI) program, which targets a patient population of at least 60,000 in the covered geographies, aiming to replicate the success of Crysvita [3][4] - The ORBIT trial has enrolled an additional 159 patients, maintaining a two-to-one randomization of setrusumab to placebo, with a focus on patients aged 5 to 26 [10][12] Market Data and Key Metrics Changes - The company is preparing for a market launch of setrusumab, which is positioned as a superior treatment compared to bisphosphonates, currently the only available treatment for OI [2][11] - The potential market for Sanfilippo is estimated at 3,000 to 5,000 patients, while GSD1A is slightly larger at 6,000 patients, indicating a strategic focus on rare disease markets [42] Company Strategy and Development Direction - The company is committed to not compromising the quality of data for the OI filing, despite the ambitious timeline for approval by the end of September [30][32] - The strategy includes leveraging AI for data analysis and document preparation to enhance efficiency in the filing process [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the probability of success for the final data readout, maintaining that the interim analyses have not negatively impacted their outlook [20][28] - The company is optimistic about achieving profitability within the timeframe of their recent monetization deal, which allows for revenue generation without immediate repayment obligations [93] Other Important Information - The company is actively working on gene therapy programs, with a focus on Sanfilippo and GSD1A, both of which are expected to have PDUFA dates within the PRV window [38][39] - The company has learned from previous regulatory feedback, applying those lessons to improve the quality of their gene therapy programs [40][42] Q&A Session Summary Question: What is the timeline for the data readout for setrusumab? - The company has defined the end of year as December or January for the data readout [34] Question: How does the company view the efficacy of bisphosphonates compared to setrusumab? - Management estimates the treatment effect of bisphosphonates to be around 20%, while setrusumab has shown a 67% reduction in fracture rates [14][15] Question: What is the company's approach to the upcoming regulatory filings? - The company plans to ensure high-quality data packages for regulatory submissions, emphasizing that they will not rush the process [30][32] Question: How does the company plan to address the market for Sanfilippo and GSD1A? - The company is confident in the clinical data for both programs and is preparing for timely submissions to the FDA [38][39]